Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

Model scores of the 29,894 trials active now.

Model score 30% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 29% of the time (655 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patient hasleukemiathe patientacuterelapsed
  Phrases that lowered it: accordingto evaluateevaluate theopen labelefficacy
• Sponsor's past termination rate: 14.9% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 99.4% (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: 24.4% (raises risk) · Drug's FDA history
• Maximum age: 20 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 24 (lowers risk) · Sponsor's track record
• Minimum age: 1 (raises risk) · Who can join
• Collaborators: 0 (raises risk) · Design
• Disease area, dermatology: No (lowers risk) · Disease area
• Sponsor's past trials: 47 (raises risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 85 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Bendamustine in Acute Leukemia and MDS NCT00790855 · started 2008 · scored riskier than 80% of active trials terminated
• Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies NCT01900509 · started 2013 · scored riskier than 91% of active trials completed
• Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) NCT02393859 · started 2015 · scored riskier than 60% of active trials completed
• Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy NCT00863850 · started 2009 · scored riskier than 33% of active trials completed
• A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL) NCT00991133 · started 2009 · scored riskier than 82% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.